Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正 式向欧洲公告机构递交CE MDR认证的全部申请资料。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 自願性公告 CARDIOVALVE三尖瓣置換遞交CE MDR認證申請 本 公 告 乃 由 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，為 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 及 新 產品研發進度的更新資料。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，於 近 日，本 集 團 已 就Cardiovalve經 導 管 三 尖 瓣 置 換 系 統（「Cardiovalve系 統」）正 式 向 歐 洲 公 告 機 構 遞 交CE ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Qiming Medical-B (02500.HK) by 10,300 shares on December 22, with a total net reduction of 116,500 shares over the past five trading days and 613,500 shares over the past twenty trading days [1] - As of now, southbound funds hold 52,929,100 shares of Qiming Medical-B, which accounts for 11.99% of the company's total issued ordinary shares [1] Group 2 - Qiming Medical Technology Co., Ltd. is primarily engaged in the research, production, and sales of biological heart valves, focusing on minimally invasive medical devices and auxiliary instruments for treating heart valve diseases [1] - The company's product line includes devices for interventional treatment of various heart valve diseases, such as aortic valve, pulmonary valve, mitral valve, and tricuspid valve, as well as systems for radiofrequency ablation and renal denervation [1] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolism protection device, with operations in both domestic and overseas markets [1]

Market Overview - A-shares experienced slight fluctuations in early trading, with major indices showing mixed results; the Shanghai Composite Index, North China 50, and CSI 1000 slightly rose, while the Shenzhen Component, Sci-Tech 50, and ChiNext Index slightly declined [1] - The number of rising stocks significantly outnumbered declining ones, and trading volume remained stable [1] Commercial Aerospace Sector - The commercial aerospace and satellite navigation concept stocks were active, with Starry Technology hitting a 30% limit up, Tianyin Electromechanical quickly reaching a 20% limit up, and several other stocks also experiencing strong gains [2] - Aerospace equipment, military electronics, military information technology, and large aircraft sectors showed strong upward momentum, with multiple stocks hitting limit up [5] Satellite Communication Development - The Ministry of Industry and Information Technology proposed that by 2030, the satellite communication management system and policies will be further improved, with over 10 million satellite communication users expected [5] - The GW constellation plan led by China Satellite Network Group has launched a total of 116 satellites as of November, which is less than 1% of the planned total of 12,992 satellites [5] - According to the International Telecommunication Union, 10% of the satellite deployment (approximately 1,300 satellites) must be completed by 2026 to meet frequency resource application requirements [5] Pharmaceutical Sector - Pharmaceutical stocks collectively strengthened in the morning, with the pharmaceutical commercial sector leading the gains, and the sector index rising nearly 3% at one point [6] - Notable stocks included Huaren Health hitting a 20% limit up, and Luyan Pharmaceutical achieving a limit up for the second consecutive day, reaching an 8.5-year high [6] - The new national medical insurance drug list, which adds 114 new drugs including 50 innovative drugs, will be implemented nationwide on January 1, 2026 [6] Industry Consolidation - Domestic pharmaceutical distribution industry still has significant room for improvement in market concentration compared to the 96% market share of the top three pharmaceutical distribution companies in the U.S. [7] - The new round of state-owned enterprise reforms emphasizing professional integration in the pharmaceutical health sector is expected to accelerate mergers and acquisitions in the pharmaceutical commercial sector [7]

杭州启明医疗器械股份有限公司是一家主要从事生物心脏瓣膜的研发以及生产及销售从事生物心脏瓣膜 的研发以及生产及销售的中国公司。该公司主要从事用于治疗心脏瓣膜疾病的微创医疗设备以及辅助仪 器和设备的研发、制造和销售。该公司的产品线已覆盖针对主动脉瓣、肺动脉瓣、二尖瓣、三尖瓣等心 脏瓣膜类疾病介入治疗系列器械、肥厚型心肌病介入治疗的射频消融系统、高血介入治疗的肾动脉去交 感神经超声消融系统以及其它手术配套耗材等。该公司的主要产品包括VenusA-Valve系統，VenusA-Plus 系統，VenusA-Pilot系統，VenusP-Valve系統，TMVR 瓣膜, TTVR 瓣膜，瓣膜成形术球囊V8/TAV8及 TriGUARD3脑栓塞保护仪器。该公司主要在中国国内和海外市场开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月11日南向资金减持5000.0股启明医疗-B（02500.HK）。近5个交易日中，获南向资 金减持的有5天，累计净减持2.1万股。近20个交易日中，获南向资金减持的有20天，累计净减持6 ...

Core Viewpoint - The article discusses a medical dispute involving high costs of heart valve implants, highlighting a crisis of trust between patients and healthcare providers in China, particularly regarding the pricing of medical devices and transparency in the healthcare system [1][2][4]. Group 1: Medical Costs and Pricing Dispute - The total medical cost for patient Li amounted to 613,200 yuan, with 320,000 yuan being out-of-pocket expenses, of which 280,000 yuan (87.5%) was for the heart valve implant [2][3]. - The hospital claims that the heart valve and related equipment were procured through a legal bidding process, adhering to a "zero markup" policy, charging patients the actual procurement price of 280,000 yuan [3][4]. - The family of the patient raised concerns about the pricing, noting that the factory price of the valve was only 38,000 yuan, leading to allegations of excessive charges [1][2]. Group 2: Regulatory and Compliance Issues - The hospital faced scrutiny for various compliance issues, including improper billing practices and exceeding insurance coverage limits, with 26 identified violations totaling 75,060.4 yuan [4][5]. - Investigations confirmed that the heart valve used was a qualified product and that the procurement process was compliant with regulations [4][6]. - The hospital acknowledged other violations, such as failure to properly label medical supplies and billing for items not covered by insurance [5]. Group 3: Market Transparency and Industry Dynamics - The heart valve market is becoming increasingly transparent, with patients able to access pricing information through various channels, reflecting a shift towards greater market openness [6][7]. - The article notes that the heart valve market is dominated by foreign companies and a few domestic players, indicating a competitive landscape that is evolving with new entrants [6][7]. - The push for transparency in medical device pricing is seen as a response to past issues of inflated costs, with ongoing efforts to ensure that pricing mechanisms are fair and reflect the true costs of production and distribution [7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州啓明醫療器械股份有限公司 (「本公司」) 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02500 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 2. 股份分類 | 普通股 | 股份 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 茲提述杭州啓明醫療器械股份有限公司（「本公司」）日期為2025年11月12日的通函（「通 函」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 通 函 所 界 定 者 具 有 相 同 涵 義。 董 事 會 謹 此 宣 佈，於 臨 時 股 東 會（「臨時股東會」）提 呈 之 決 議 案 已 獲 正 式 通 過。 臨時股東會於2025年11月28日（星 期 五）假 座 中 國 杭 州 濱 江 區 江 陵 路88號2幢3樓311 室舉行。 臨時股東會之表決結果 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 臨時股東會之表決結果 於 臨 時 股 東 會 日 期，(i)已發行股份總數為441,011,443股 股 份，包 括4 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Qiming Medical-B (02500.HK) by 12,500 shares on November 26, 2025, marking a total net reduction of 383,500 shares over the past five trading days and 735,500 shares over the past twenty trading days [1][2] - As of now, southbound funds hold 53,061,100 shares of Qiming Medical-B, which accounts for 12.02% of the company's total issued ordinary shares [1][2] Group 2 - Qiming Medical Co., Ltd. specializes in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices and auxiliary instruments for treating heart valve diseases [2] - The company's product line includes devices for interventional treatment of various heart valve diseases, such as aortic valve, pulmonary valve, mitral valve, and tricuspid valve, as well as systems for radiofrequency ablation and ultrasound ablation for hypertension treatment [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolism protection device, with operations in both domestic and overseas markets [2]

Core Insights - The article highlights the significant transformation in local fiscal revenue patterns in China as of the third quarter of 2025, with cities like Shanghai, Beijing, and Shenzhen leading in fiscal income, reflecting the country's shift towards high-quality economic development [1][10]. Group 1: Fiscal Revenue Rankings - Shanghai ranks first with a fiscal revenue of 655.57 billion, followed by Beijing at 503.99 billion and Shenzhen at 313.21 billion [6]. - Hangzhou maintains the fourth position with 220 billion, while Tianjin surpasses Guangzhou with 167.8 billion compared to Guangzhou's 163.21 billion [6][10]. - Hefei enters the top twenty for the first time with a notable performance of 74.58 billion [1][6]. Group 2: Economic Drivers - Hangzhou's fiscal resilience is attributed to its strong digital economy, with a slight increase in public budget revenue and significant contributions from tech giants like Ant Group and Alibaba Cloud [3]. - Tianjin's growth is driven by the implementation of the Beijing-Tianjin-Hebei coordinated development strategy, with new projects in aerospace and petrochemicals boosting tax revenue [5][10]. - Hefei's remarkable growth in the new energy vehicle sector, with a 42% increase in tax revenue, showcases its successful long-term investment strategy in technology and innovation [7]. Group 3: Insights Beyond the Data - The article emphasizes that fiscal health should be assessed through various dimensions, including industrial structure and innovation concentration, rather than solely relying on revenue rankings [9]. - Cities like Ningbo and Xi'an demonstrate strong potential despite their current rankings, indicating that future market dynamics may shift based on emerging industries [9][10]. - Guangzhou's growth in the new generation information technology service sector, with a 24% tax revenue increase, suggests a possible future reshaping of the economic landscape [9].